NASDAQ:LYEL Lyell Immunopharma (LYEL) Stock Price, News & Analysis $9.70 +0.90 (+10.23%) Closing price 04:00 PM EasternExtended Trading$9.75 +0.05 (+0.52%) As of 06:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Lyell Immunopharma Stock (NASDAQ:LYEL) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Lyell Immunopharma alerts:Sign Up Key Stats Today's Range$8.56▼$10.0150-Day Range$7.51▼$15.7952-Week Range$7.20▼$45.00Volume158,615 shsAverage Volume133,958 shsMarket Capitalization$237.65 millionP/E RatioN/ADividend YieldN/APrice Target$40.86Consensus RatingModerate Buy Company Overview Lyell Immunopharma, Inc. is a clinical-stage biotechnology company focused on developing engineered T-cell therapies for cancer, with an emphasis on solid tumors. The company seeks to address limitations of existing cell therapies, including T-cell exhaustion, limited persistence and reduced activity within the tumor microenvironment. Lyell uses cell-engineering and genomic technologies to develop investigational chimeric antigen receptor (CAR) T-cell and T-cell receptor (TCR) therapies. Its research programs are designed to improve the fitness, durability and antitumor performance of therapeutic T cells, and its pipeline has included programs directed at targets such as ROR1. Founded in 2018, Lyell Immunopharma is headquartered in South San Francisco, California, and conducts research and clinical-development activities through collaborations and clinical trials. The company’s therapies remain investigational and are being evaluated for potential use in patients with cancer.AI Generated. May Contain Errors. Read More Lyell Immunopharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks57th Percentile Overall ScoreLYEL MarketRank™: 2.82591362126 of 5 starsLyell Immunopharma scored higher than 57% of companies evaluated by MarketBeat, and ranked 416th out of 903 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingLyell Immunopharma has received a consensus rating of Moderate Buy. The company's average rating score is 2.78, and is based on 1 strong buy rating, 6 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialLyell Immunopharma has a consensus price target of $40.86, representing about 321.2% upside from its current price of $9.70.Amount of Analyst CoverageLyell Immunopharma has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Lyell Immunopharma's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Lyell Immunopharma are expected to decrease in the coming year, from ($7.16) to ($7.21) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Lyell Immunopharma is -0.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Lyell Immunopharma is -0.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLyell Immunopharma has a P/B Ratio of 0.83. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Lyell Immunopharma's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted5.50% of the float of Lyell Immunopharma has been sold short.Short Interest Ratio / Days to CoverLyell Immunopharma has a short interest ratio ("days to cover") of 7.4.Change versus previous monthShort interest in Lyell Immunopharma has recently increased by 6.36%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldLyell Immunopharma does not currently pay a dividend.Dividend GrowthLyell Immunopharma does not have a long track record of dividend growth. News and Social Media1.8 / 5News Sentiment-0.04 News SentimentLyell Immunopharma has a news sentiment score of -0.04. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.46 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Lyell Immunopharma this week, compared to 2 articles on an average week.MarketBeat Follows1 people have added Lyell Immunopharma to their MarketBeat watchlist in the last 30 days. Company Ownership1.7 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Lyell Immunopharma insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $22,052.00 in company stock.Percentage Held by Insiders6.20% of the stock of Lyell Immunopharma is held by insiders.Percentage Held by Institutions66.05% of the stock of Lyell Immunopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Lyell Immunopharma's insider trading history. Receive LYEL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lyell Immunopharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. LYEL Stock News HeadlinesLyell Immunopharma (NASDAQ:LYEL) Rating Lowered to "Sell" at Wall Street ZenOctober 19 at 2:00 AM | americanbankingnews.comCritical Survey: Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) and Lyell Immunopharma (NASDAQ:LYEL)October 17 at 2:15 AM | americanbankingnews.comFederal Reserve’s Disturbing Plan To Control Your MoneyA Federal Reserve filing, Docket No. OP-1670, is drawing scrutiny for language that could expand the Fed's visibility into consumer bank transactions. A pilot program is reportedly already underway, with wider rollout at major banks possibly beginning this summer. Martin D. Weiss, PhD, founder of Weiss Ratings, breaks down what the document says and what steps account holders might consider.October 20 at 1:00 AM | Weiss Ratings (Ad)Analysts Are Bullish on These Healthcare Stocks: Lineage Therap (LCTX), Lyell Immunopharma (LYEL)September 26, 2026 | theglobeandmail.comLyell Immunopharma To Participate in the Baird 2026 Global Healthcare ConferenceSeptember 14, 2026 | globenewswire.comLyell Immunopharma Completes Manufacturing Transfer for LYL273 and Provides Updated Timeline on Phase 1/2 Trial in Metastatic Colorectal CancerSeptember 10, 2026 | globenewswire.comLyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2026August 7, 2026 | finance.yahoo.comLyell Immunopharma Announces Participation in H.C. Wainwright 4th Annual Cell Therapy Virtual ConferenceJune 25, 2026 | globenewswire.comSee More Headlines LYEL Stock Analysis - Frequently Asked Questions How have LYEL shares performed this year? Lyell Immunopharma's stock was trading at $30.78 at the start of the year. Since then, LYEL shares have decreased by 68.5% and is now trading at $9.70. How were Lyell Immunopharma's earnings last quarter? Lyell Immunopharma, Inc. (NASDAQ:LYEL) posted its quarterly earnings results on Thursday, August, 6th. The company reported ($1.92) earnings per share for the quarter, topping analysts' consensus estimates of ($1.94) by $0.02. The business had revenue of $0 million for the quarter, compared to analyst estimates of $0 million. Lyell Immunopharma had a negative net margin of 920,285.25% and a negative trailing twelve-month return on equity of 91.62%. When did Lyell Immunopharma's stock split? Lyell Immunopharma's stock reverse split on the morning of Friday, May 30th 2025.The 1-20 reverse split was announced on Friday, May 30th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Friday, May 30th 2025. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. When did Lyell Immunopharma IPO? Lyell Immunopharma (LYEL) raised $425 million in an initial public offering on Tuesday, June 15th 2021. The company issued 25,000,000 shares at $16.00-$18.00 per share. Goldman Sachs, BofA Securities, J.P. Morgan and Morgan Stanley acted as the underwriters for the IPO. How do I buy shares of Lyell Immunopharma? Shares of LYEL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Lyell Immunopharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Lyell Immunopharma investors own include NVIDIA (NVDA), Recursion Pharmaceuticals (RXRX), SoFi Technologies (SOFI), SoundHound AI (SOUN), fuboTV (FUBO), Allogene Therapeutics (ALLO) and Advanced Micro Devices (AMD). Company Calendar Last Earnings8/06/2026Today10/20/2026Next Earnings (Estimated)11/10/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (3w+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 For the last 3 weeks, LYEL's financial health has been in the Red zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:LYEL CIK1806952 Webwww.lyell.com Phone650-695-0677FaxN/AEmployees161Year Founded2018Price Target and Rating Average Price Target for Lyell Immunopharma$40.86 High Price Target$49.00 Low Price Target$34.00 Potential Upside/Downside+321.2%Consensus RatingModerate Buy Rating Score (0-4)2.78 Research Coverage9 Analysts Profitability EPS (Trailing Twelve Months)($12.83) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$274.45 million Net Margins-920,285.25% Pretax Margin-920,285.19% Return on Equity-91.62% Return on Assets-70.50% Debt Debt-to-Equity RatioN/A Current Ratio5.36 Quick Ratio5.36 Sales & Book Value Annual Sales$40 thousand Price / Sales5,941.25 Cash FlowN/A Price / Cash FlowN/A Book Value$11.68 per share Price / Book0.83Miscellaneous Outstanding Shares24,500,000Free Float22,985,000Market Cap$237.65 million OptionableOptionable Beta-0.03 Social Links 7 Blue-Chip Stocks to Add To Your Forever PortfolioA strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership. This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.Get This Free Report This page (NASDAQ:LYEL) was last updated on 10/20/2026 by MarketBeat.com Staff. From Our PartnersTrump’s Plan To Cheat HistoryChina has slashed its U.S. Treasury holdings by more than 45% from their peak, while building gold vaults and ...Porter & Company | SponsoredFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leadin...Weiss Ratings | SponsoredLast call for your free 0DTE reportThe 0DTE Game Plan lays out a simple 3-step framework for trading same-day options: Plan it, profit from it, p...Profits Run | SponsoredINSANE DRONE FOOTAGENew drone footage shows a mysterious factory rising at one of Elon Musk's most secure facilities, cleared and ...Paradigm Press | SponsoredYour book is insideBlane Markham and the Markham Trading Team are giving readers a limited window to download their options strat...TradeWins | SponsoredThe Iran War Isn’t Chaos. It’s Strategy.Two thousand missiles struck Iran. Three days later, Dylan Jovine sat in two private meetings with U.S. Congre...Behind the Markets | SponsoredIf you keep cash in a U.S. bank account… read this NOWSince 2020, U.S. banks have been required to keep zero percent of deposits on hand, lending out nearly every d...Banyan Hill Publishing | SponsoredBuy These Five AI Plays Before October 20Jeff Brown, founder and CEO of Brownstone Research, says a new market cycle he calls the million dollar cycle ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lyell Immunopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lyell Immunopharma With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
